{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:56:43Z","timestamp":1791039403778,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH (NIMH and NINDS)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.phrs.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T14:18:32Z","timestamp":1392387512000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Pharmacological chaperoning: A primer on mechanism and pharmacology"],"prefix":"10.1016","volume":"83","author":[{"given":"Nancy J.","family":"Leidenheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn G.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.01.005_bib0005","first-page":"3","article-title":"Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis","author":"Lindquist","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-385952-5.00008-7","article-title":"Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors","volume":"62","author":"Conn","year":"2011","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0015","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2012.11.006","article-title":"Novel pharmacological strategies to treat cystic fibrosis","volume":"34","author":"Hanrahan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1208\/s12248-009-9090-7","article-title":"Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery","volume":"11","author":"Lester","year":"2009","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.phrs.2014.01.005_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mce.2013.06.024","article-title":"Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function","volume":"382","author":"Ulloa-Aguirre","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2014.01.005_bib0035","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.01.005_bib0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-4159.2010.06821.x","article-title":"Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2","volume":"114","author":"Calvo","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/ddq085","article-title":"Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo","volume":"19","author":"Gersting","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0050","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/hmg\/dds001","article-title":"Novel pharmacological chaperones that correct phenylketonuria in mice","volume":"21","author":"Santos-Sierra","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0055","doi-asserted-by":"crossref","first-page":"21030","DOI":"10.1073\/pnas.1315194110","article-title":"Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy","volume":"110","author":"Janovick","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.01.005_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2014.01.005_bib0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.phrs.2014.01.005_bib0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.phrs.2014.01.005_bib0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.phrs.2014.01.005_bib0085","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2004-2071","article-title":"In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles","volume":"90","author":"Leanos-Miranda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.01.005_bib0090","doi-asserted-by":"crossref","first-page":"a007526","DOI":"10.1101\/cshperspect.a007526","article-title":"Protein folding and quality control in the ER","volume":"3","author":"Araki","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0095","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1110\/ps.0240003","article-title":"Protein stability induced by ligand binding correlates with changes in protein flexibility","volume":"12","author":"Celej","year":"2003","journal-title":"Protein Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0105","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0110","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2014.01.005_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/jhg.2011.36","article-title":"Biochemical and structural study on a S529V mutant acid alpha-glucosidase responsive to pharmacological chaperones","volume":"56","author":"Tajima","year":"2011","journal-title":"J Hum Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.phrs.2014.01.005_bib0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/glycob\/7.2.277","article-title":"Active-site motifs of lysosomal acid hydrolases: invariant features of clan GH-A glycosyl hydrolases deduced from hydrophobic cluster analysis","volume":"7","author":"Durand","year":"1997","journal-title":"Glycobiology"},{"key":"10.1016\/j.phrs.2014.01.005_bib0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/hmg\/9.6.967","article-title":"Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis","volume":"9","author":"Durand","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0140","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.2174\/1568026611212220008","article-title":"Phenylalanine hydroxylase misfolding and pharmacological chaperones","volume":"12","author":"Underhaug","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0145","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/cbic.201200188","article-title":"Structural and mechanistic basis of the interaction between a pharmacological chaperone and human phenylalanine hydroxylase","volume":"13","author":"Torreblanca","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nsmb882","article-title":"The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR","volume":"12","author":"Du","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0155","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1091\/mbc.E08-09-0950","article-title":"Cooperative assembly and misfolding of CFTR domains in vivo","volume":"20","author":"Du","year":"2009","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.phrs.2014.01.005_bib0160","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.1021\/bi9004842","article-title":"Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule","volume":"48","author":"Loo","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2014.01.005_bib0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/mol.110.065862","article-title":"A chemical corrector modifies the channel function of F508del-CFTR","volume":"78","author":"Kim Chiaw","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0170","doi-asserted-by":"crossref","first-page":"24714","DOI":"10.1074\/jbc.M111.239699","article-title":"Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant","volume":"286","author":"Yu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0175","doi-asserted-by":"crossref","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","article-title":"The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis","volume":"285","author":"Thibodeau","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2014.01.005_bib0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cell.2011.11.024","article-title":"Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function","volume":"148","author":"Rabeh","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2014.01.005_bib0190","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1124\/mol.109.055608","article-title":"A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability","volume":"75","author":"Wellhauser","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0195","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.01.005_bib0200","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bcp.2013.06.028","article-title":"Corrector VX-809 stabilizes the first transmembrane domain of CFTR","volume":"86","author":"Loo","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0205","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1096\/fj.12-216119","article-title":"Correctors of DeltaF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein","volume":"27","author":"He","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores DeltaF508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/BJ20070478","article-title":"Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants","volume":"406","author":"Wang","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0220","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2119\/molmed.2012.00001","article-title":"Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform","volume":"18","author":"Holleran","year":"2012","journal-title":"Mol Med"},{"issue":"5","key":"10.1016\/j.phrs.2014.01.005_bib0225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40272-013-0035-3","article-title":"Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors","volume":"15","author":"Galietta","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.phrs.2014.01.005_bib0230","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/mi.2.5.308","article-title":"Protein origami: therapeutic rescue of misfolded gene products","volume":"2","author":"Conn","year":"2002","journal-title":"Mol Interv"},{"key":"10.1016\/j.phrs.2014.01.005_bib0235","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1074\/jbc.M510601200","article-title":"Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy","volume":"281","author":"Janovick","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tips.2009.02.002","article-title":"Drug development and the cellular quality control system","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.10.051","article-title":"Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease","volume":"299","author":"Conn","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mce.2011.01.016","article-title":"Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism","volume":"337","author":"Maya-Nunez","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0255","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1210\/jc.2002-020961","article-title":"Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism","volume":"87","author":"Leanos-Miranda","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.01.005_bib0260","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/cb600360h","article-title":"G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease","volume":"1","author":"Ulloa-Aguirre","year":"2006","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0265","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"Wuller","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0270","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1016\/j.febslet.2005.08.043","article-title":"The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding","volume":"579","author":"Thielen","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.phrs.2014.01.005_bib0275","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1096\/fj.08-125385","article-title":"Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum","volume":"23","author":"Yasuda","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0280","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1523\/JNEUROSCI.21-04-01189.2001","article-title":"C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors","volume":"21","author":"Pagano","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0285","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1054-3589(10)58004-9","article-title":"Mechanisms of GABAB receptor exocytosis, endocytosis, and degradation","volume":"58","author":"Benke","year":"2010","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/BJ20081227","article-title":"Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers","volume":"417","author":"Canals","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0295","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1600-0854.2009.00932.x","article-title":"Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones","volume":"10","author":"Kobayashi","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2014.01.005_bib0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jmg.31.2.89","article-title":"The molecular basis of genetic dominance","volume":"31","author":"Wilkie","year":"1994","journal-title":"J Med Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0305","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/hmg\/11.20.2435","article-title":"Ion channel diseases","volume":"11","author":"Hubner","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/path.2583","article-title":"Dominant negative factors in health and disease","volume":"218","author":"Veitia","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0315","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1093\/hmg\/ddn202","article-title":"Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa","volume":"17","author":"Mendes","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.phrs.2014.01.005_bib0320","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1074\/jbc.M111.305656","article-title":"Cys-27 variant of human delta-opioid receptor modulates maturation and cell surface delivery of Phe-27 variant via heteromerization","volume":"287","author":"Leskela","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0325","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1210\/me.2004-0091","article-title":"Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect","volume":"18","author":"Brothers","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0330","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.1074\/jbc.M501978200","article-title":"Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants","volume":"280","author":"Knollman","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0335","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bcp.2013.07.001","article-title":"Structural insights into Cys-loop receptor function and ligand recognition","volume":"86","author":"Nys","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0340","doi-asserted-by":"crossref","first-page":"28721","DOI":"10.1074\/jbc.273.44.28721","article-title":"Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0345","doi-asserted-by":"crossref","first-page":"11554","DOI":"10.1523\/JNEUROSCI.23-37-11554.2003","article-title":"Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons","volume":"23","author":"Nashmi","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0350","doi-asserted-by":"crossref","first-page":"18767","DOI":"10.1074\/jbc.M308260200","article-title":"An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotine","volume":"279","author":"Sallette","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0355","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2005.03.029","article-title":"Nicotine upregulates its own receptors through enhanced intracellular maturation","volume":"46","author":"Sallette","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2014.01.005_bib0360","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1124\/mol.105.012419","article-title":"Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors","volume":"68","author":"Kuryatov","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0365","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2007.06.040","article-title":"Cell autonomy, receptor autonomy, and thermodynamics in nicotine receptor up-regulation","volume":"74","author":"Nashmi","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0370","doi-asserted-by":"crossref","first-page":"12316","DOI":"10.1523\/JNEUROSCI.2393-13.2013","article-title":"Nicotine-modulated subunit stoichiometry affects stability and trafficking of alpha3beta4 nicotinic receptor","volume":"33","author":"Mazzo","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0375","doi-asserted-by":"crossref","first-page":"e62246","DOI":"10.1371\/journal.pone.0062246","article-title":"Chemical chaperones exceed the chaperone effects of RIC-3 in promoting assembly of functional alpha7 AChRs","volume":"8","author":"Kuryatov","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2014.01.005_bib0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1085\/jgp.201010532","article-title":"Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning","volume":"137","author":"Srinivasan","year":"2011","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0385","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/mol.108.054494","article-title":"Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy","volume":"75","author":"Son","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-385952-5.00007-5","article-title":"Regulation of stability and trafficking of calcium-sensing receptors by pharmacologic chaperones","volume":"62","author":"Huang","year":"2011","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0395","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00406.2012","article-title":"Pharmacological correction of long QT-linked mutations in KCHN2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional ER","author":"Smith","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0400","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.phrs.2014.01.005_bib0405","first-page":"C919","article-title":"Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor","volume":"305","author":"Hawtin","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mce.2007.04.012","article-title":"Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro","volume":"272","author":"Janovick","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0415","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2014.01.005_bib0420","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.physiol.63.1.607","article-title":"Nephrogenic diabetes insipidus","volume":"63","author":"Morello","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0425","doi-asserted-by":"crossref","first-page":"42198","DOI":"10.1074\/jbc.M510180200","article-title":"Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b\/V3 receptor by a pharmacological chaperone","volume":"280","author":"Robert","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0430","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1210\/me.2004-0301","article-title":"A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking","volume":"19","author":"Fan","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0435","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1074\/jbc.M511765200","article-title":"Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome","volume":"281","author":"Gong","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0440","doi-asserted-by":"crossref","first-page":"33333","DOI":"10.1074\/jbc.M109.043364","article-title":"Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal","volume":"284","author":"Noorwez","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0445","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1677\/jme.1.02142","article-title":"Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression","volume":"37","author":"Brothers","year":"2006","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0450","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/jpet.107.134502","article-title":"Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622","volume":"325","author":"Norez","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2014.01.005_bib0455","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1124\/mol.110.063511","article-title":"Pharmacochaperoning of the A1 adenosine receptor is contingent on the endoplasmic reticulum","volume":"77","author":"Malaga-Dieguez","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0460","doi-asserted-by":"crossref","first-page":"e65767","DOI":"10.1371\/journal.pone.0065767","article-title":"Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor","volume":"8","author":"Labrecque","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2014.01.005_bib0465","doi-asserted-by":"crossref","first-page":"40838","DOI":"10.1074\/jbc.M110.142257","article-title":"ANKRD13C acts as a molecular chaperone for G protein-coupled receptors","volume":"285","author":"Parent","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0470","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/emboj\/21.7.1628","article-title":"Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation","volume":"21","author":"Petaja-Repo","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0475","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1074\/jbc.M107345200","article-title":"The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations","volume":"277","author":"Ficker","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0480","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.102.048454","article-title":"Structure\u2013activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor","volume":"305","author":"Janovick","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2014.01.005_bib0485","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/mol.111.075135","article-title":"Molecular determinants of pentamidine-induced hERG trafficking inhibition","volume":"81","author":"Dennis","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0490","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0495","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0500","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0505","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1074\/jbc.M312810200","article-title":"Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor","volume":"279","author":"Yan","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0510","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00041552-200011000-00001","article-title":"Nephrogenic diabetes insipidus","volume":"9","author":"Deen","year":"2000","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.phrs.2014.01.005_bib0515","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.phrs.2014.01.005_bib0520","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1111\/j.1742-4658.2007.06040.x","article-title":"Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells","volume":"274","author":"Tropak","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0525","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/glycob\/cwp183","article-title":"A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates","volume":"20","author":"Tropak","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.phrs.2014.01.005_bib0530","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0535","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/mol.64.1.32","article-title":"Rescuing the traffic-deficient mutants of rat mu-opioid receptors with hydrophobic ligands","volume":"64","author":"Chaipatikul","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0540","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1681\/ASN.2008121289","article-title":"Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus","volume":"20","author":"Jean-Alphonse","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0545","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2826.2010.01983.x","article-title":"Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus","volume":"22","author":"Los","year":"2010","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0550","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/me.2007-0092","article-title":"Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling","volume":"21","author":"van den Eijnden","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0555","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1074\/jbc.M111.268797","article-title":"V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists","volume":"287","author":"Takahashi","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0560","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1210\/me.2009-0041","article-title":"Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants","volume":"23","author":"White","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0565","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1074\/jbc.M110.124792","article-title":"Calcium-sensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retention","volume":"285","author":"Cavanaugh","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0570","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1073\/pnas.1015723108","article-title":"Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist","volume":"108","author":"Newton","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.01.005_bib0575","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mce.2008.09.015","article-title":"Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine","volume":"298","author":"Janovick","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0580","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.phrs.2014.01.005_bib0585","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.abb.2012.12.017","article-title":"A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics","volume":"530","author":"Jaffe","year":"2013","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.phrs.2014.01.005_bib0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/mol.106.023994","article-title":"Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones","volume":"70","author":"Wang","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0595","doi-asserted-by":"crossref","first-page":"20942","DOI":"10.1074\/jbc.M113.470948","article-title":"Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism","volume":"288","author":"Chen","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0600","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/mol.109.061804","article-title":"Functional characterization of vasopressin type 2 receptor substitutions (R137H\/C\/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments","volume":"77","author":"Rochdi","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0605","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0610","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0854.2008.00846.x","article-title":"Phe27Cys polymorphism alters the maturation and subcellular localization of the human delta opioid receptor","volume":"10","author":"Leskela","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2014.01.005_bib0615","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/BJ20071420","article-title":"Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones","volume":"410","author":"Varga","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2014.01.005_bib0620","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1242\/jcs.120196","article-title":"Regulated recycling of mutant CFTR is partially restored by pharmacological treatment","volume":"126","author":"Holleran","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0625","doi-asserted-by":"crossref","first-page":"e1000155","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0630","doi-asserted-by":"crossref","first-page":"17400","DOI":"10.1073\/pnas.1203924109","article-title":"Pharmacological chaperones for human alpha-N-acetylgalactosaminidase","volume":"109","author":"Clark","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.01.005_bib0635","doi-asserted-by":"crossref","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2014.01.005_bib0640","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/jpet.106.107987","article-title":"Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists","volume":"319","author":"Chen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2014.01.005_bib0645","doi-asserted-by":"crossref","first-page":"23171","DOI":"10.1074\/jbc.M610896200","article-title":"Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum","volume":"282","author":"Leskela","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0650","doi-asserted-by":"crossref","first-page":"19350","DOI":"10.1074\/jbc.M414043200","article-title":"Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis","volume":"280","author":"Van Craenenbroeck","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0655","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lfs.2006.08.024","article-title":"Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor","volume":"80","author":"Van Craenenbroeck","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0660","doi-asserted-by":"crossref","first-page":"39201","DOI":"10.1074\/jbc.M110.118000","article-title":"Mutations in the carboxyl-terminal SEC24 binding motif of the serotonin transporter impair folding of the transporter","volume":"285","author":"El-Kasaby","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0665","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.biopsych.2012.05.020","article-title":"Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects","volume":"72","author":"Lester","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.phrs.2014.01.005_bib0670","doi-asserted-by":"crossref","first-page":"17139","DOI":"10.1074\/jbc.M200363200","article-title":"Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels","volume":"277","author":"Taschenberger","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0675","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1152\/jn.00117.2007","article-title":"Lidocaine promotes the trafficking and functional expression of Na(v)1.8 sodium channels in mammalian cells","volume":"98","author":"Zhao","year":"2007","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0680","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fphys.2013.00386","article-title":"Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels","volume":"4","author":"Martin","year":"2013","journal-title":"Front Physiol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0685","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1074\/jbc.M111.275438","article-title":"Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1\/ABCB4","volume":"287","author":"Gautherot","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0690","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjp.0706892","article-title":"Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine","volume":"149","author":"Rajamani","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0695","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00210-010-0583-9","article-title":"hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine","volume":"383","author":"Staudacher","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0700","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1124\/mol.108.053793","article-title":"Intracellular potassium stabilizes human ether-a-go-go-related gene channels for export from endoplasmic reticulum","volume":"75","author":"Wang","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0705","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.01.005_bib0710","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0854.2004.00232.x","article-title":"Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease","volume":"5","author":"Ulloa-Aguirre","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2014.01.005_bib0715","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1074\/jbc.M609045200","article-title":"Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis","volume":"282","author":"Huang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0720","doi-asserted-by":"crossref","first-page":"13727","DOI":"10.1074\/jbc.275.18.13727","article-title":"Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor","volume":"275","author":"Petaja-Repo","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2010.05.030","article-title":"GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors","volume":"1346","author":"Eshaq","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2014.01.005_bib0730","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1073\/pnas.82.14.4847","article-title":"A large intracellular pool of inactive Na channel alpha subunits in developing rat brain","volume":"82","author":"Schmidt","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.01.005_bib0735","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1677\/joe.1.06771","article-title":"\u2018Effective inefficiency\u2019: cellular control of protein trafficking as a mechanism of post-translational regulation","volume":"190","author":"Conn","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.phrs.2014.01.005_bib0740","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.2174\/1568026611212220009","article-title":"Cofactors and metabolites as protein folding helpers in metabolic diseases","volume":"12","author":"Rodrigues","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0745","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1073858405283828","article-title":"Glutamate receptors and endoplasmic reticulum quality control: looking beneath the surface","volume":"12","author":"Fleck","year":"2006","journal-title":"Neuroscientist"},{"key":"10.1016\/j.phrs.2014.01.005_bib0750","doi-asserted-by":"crossref","first-page":"27432","DOI":"10.1074\/jbc.M112.345108","article-title":"Glutamate binding to the GluN2B subunit controls surface trafficking of N-methyl-d-aspartate (NMDA) receptors","volume":"287","author":"She","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0755","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1523\/JNEUROSCI.3953-08.2009","article-title":"Agonist occupancy is essential for forward trafficking of AMPA receptors","volume":"29","author":"Coleman","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0760","doi-asserted-by":"crossref","first-page":"36032","DOI":"10.1074\/jbc.M110.156943","article-title":"Ligand-binding domain determines endoplasmic reticulum exit of AMPA receptors","volume":"285","author":"Coleman","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0765","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1523\/JNEUROSCI.4573-04.2005","article-title":"Glutamate receptor trafficking: endoplasmic reticulum quality control involves ligand binding and receptor function","volume":"25","author":"Mah","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2014.01.005_bib0770","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1074\/jbc.M411549200","article-title":"Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors","volume":"280","author":"Valluru","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0775","doi-asserted-by":"crossref","first-page":"14503","DOI":"10.1074\/jbc.M900510200","article-title":"Glutamate binding and conformational flexibility of ligand-binding domains are critical early determinants of efficient kainate receptor biogenesis","volume":"284","author":"Gill","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.01.005_bib0780","doi-asserted-by":"crossref","first-page":"e22784","DOI":"10.1371\/journal.pone.0022784","article-title":"Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs","volume":"6","author":"Janovick","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2014.01.005_bib0785","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2011.00006","article-title":"Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins","volume":"2","author":"Conn","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.phrs.2014.01.005_bib0790","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/1087057113483559","article-title":"High-throughput screen for pharmacoperones of the vasopressin type 2 receptor","volume":"18","author":"Conn","year":"2013","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.phrs.2014.01.005_bib0795","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-391862-8.00001-6","article-title":"Therapeutic rescue of misfolded\/mistrafficked mutants: automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs","volume":"521","author":"Smithson","year":"2013","journal-title":"Methods Enzymol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:09:34Z","timestamp":1597475374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":159,"alternative-id":["S1043661814000139"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.01.005","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological chaperoning: A primer on mechanism and pharmacology","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}